Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging

The current gold standards for the diagnosis of bladder cancer are invasive or lack the sensitivity to correctly identify the disease. A study with bladder cancer (BC) patients of University of Texas Southwestern (Dallas) with validation in Chinese patients (Central South University of Changsa) found that urine D-dimer has a high sensitivity (97%) for discriminating BC from urology controls. Urine IL-8 and IgA may have the potential of identifying disease progression during patient follow-up. The authors conclude that the use of these urine biomarkers for initial triage could have a significant impact as the current cystoscopy-based diagnostic and surveillance approach is costly and invasive when compared to a simple urine test.